© Reuters. People queue to receive a dose of the Pfizer BioNTech vaccine at the Central Middlesex Hospital in London, Britain, August 1, 2021. REUTERS/Henry Nicholls/Files
By William Schomberg and Ludwig Burger
LONDON (Reuters) – Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
After five to six months, the effectiveness of the Pfizer (NYSE:) jab at preventing COVID-19 infection in the month after the second dose fell from 88% to 74%, an analysis of data collected in Britain’s ZOE COVID study showed.
For the AstraZeneca (NASDAQ:) vaccine, effectiveness fell from 77% to 67% after four to five months.
The updated analysis was based on data from more than a million app users during the period December 8, 2020 to July 31, 2021, comparing self-reported infections in vaccinated participants with cases in an unvaccinated control group. (https://
More data is needed in younger people because participants who had their shots up to six months ago tended to be elderly as that age group was prioritised when the shots were first approved, said the study authors, who discussed the results in an online webinar (https://
ZOE Ltd was founded three years ago to offer customised nutritional advice based on test kits. The company’s ZOE COVID Symptom Study app is a not-for-profit initiative in collaboration with King’s College London and funded by the Department of Health and Social Care.
Under a worst-case future scenario, protection could fall below 50% for older people and healthcare workers by the winter, Tim Spector, ZOE Ltd co-founder and principal investigator for the study, said.
“It’s bringing into focus this need for some action. We can’t just sit by and see the protectiveness slowly waning whilst cases are still high and the chance of infection still high as well,” Spector told BBC television.
Britain and other European nations are planning for a COVID-19 vaccine booster campaign later this year after top vaccine advisers said it might be necessary to give third shots to the elderly and most vulnerable from September.
The U.S. government is preparing to provide third booster doses starting in mid-September to Americans who had their initial course more than eight months ago.
“This is a reminder that we cannot rely on vaccines alone to prevent the spread of COVID,” said Simon Clarke, Associate Professor in Cellular Microbiology at the University of Reading, who was not involved in the study.
He cautioned that the results may have been distorted by the surge in overall cases in Britain in July.
A separate British public health study found last week that protection from either the Pfizer-BioNTech or the AstraZeneca vaccine against the now prevalent Delta variant of the coronavirus weakens within three months.
The Oxford University study found at the time that 90 days after a second shot of the Pfizer or AstraZeneca vaccine, their efficacy in preventing infections had slipped to 75% and 61% respectively. That was down from 85% and 68%, respectively, seen two weeks after a second dose.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
